Value-based decisions require us to process the benefits and costs of choice alternatives and choose the one with the highest subjective value. Thus, to obtain greater benefits, decision makers often have to incur and endure costs. In this talk, I present some recent neuropharmacological studies which show that specific interventions can facilitate the endurance of costs for the enjoyment of greater benefits. In particular, blocking D2-receptors in human participants increases their willingness to take risks and to wait for larger financial rewards. Moreover, men become more generous, i.e., more likely to endure social costs. A second line of research shows that the temporoparietal junction plays a role in overcoming delay and social costs by facilitating the perspective of others, including that of the decision make’s future self. These mechanisms of overcoming costs could provide new paths for interventions to increase cost endurance in clinical and non-clinical domains.